Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery

M. M. Swarbrick, Kimber Stanhope, I. T. Austrheim-Smith, M. D. Van Loan, Mohamed R Ali, B. M. Wolfe, Peter J Havel

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Aims/hypothesis: Bariatric surgery is an effective treatment for severe obesity, as in addition to dramatic weight loss, co-morbidities such as type 2 diabetes are frequently resolved. Although altered gastrointestinal peptide hormone secretion and its relationship with post-surgical improvements in insulin sensitivity has been studied, much less is known about long-term changes in pancreatic and adipose tissue-derived hormones. Our objective was to conduct a comprehensive longitudinal investigation of the endocrine changes following Roux-en-Y gastric bypass surgery (RYGBP), focusing on pancreatic and adipocyte hormones and systemic markers of inflammation. Methods: Nineteen severely obese women (BMI 45.6±1.6 kg/m2) were studied prior to RYGBP, and at 1, 3, 6, and 12 months after RYGBP. Body composition was assessed before surgery and at 1 and 12 months. Results: Pre-surgical adiposity was correlated with circulating adipocyte hormones (leptin, visfatin) and inflammatory molecules (IL-6, high sensitivity C-reactive protein [hsCRP], monocyte chemoattractant protein-1). As expected, RYGBP reduced fat mass and fasting insulin and glucose concentrations. In addition, reductions of fasting pancreatic polypeptide (PP) and glucagon concentrations were observed at 1 and 3 months, respectively. In the 12 months following RYGBP, concentrations of most adipocyte hormones (leptin, acylation-stimulating hormone and visfatin, but not retinol-binding hormone-4) and inflammatory molecules (IL-6, hsCRP and soluble intracellular adhesion molecule-1) were significantly reduced. Reductions of insulin resistance (measured by homeostasis model assessment of insulin resistance) were independently associated with changes of glucagon, visfatin and PP. Pre-surgical HMW adiponectin concentrations independently predicted losses of body weight and fat mass. Conclusions/interpretation: These results suggest that pancreatic and adipocyte hormones may contribute to the long-term resolution of insulin resistance after RYGBP.

Original languageEnglish (US)
Pages (from-to)1901-1911
Number of pages11
JournalDiabetologia
Volume51
Issue number10
DOIs
StatePublished - Oct 2008

Fingerprint

Pancreatic Hormones
Gastric Bypass
Adipocytes
Nicotinamide Phosphoribosyltransferase
Hormones
Insulin Resistance
Pancreatic Polypeptide
Leptin
Glucagon
C-Reactive Protein
Adipose Tissue
Interleukin-6
Fasting
Gastrointestinal Hormones
Bariatric Surgery
Morbid Obesity
Acylation
Peptide Hormones
Chemokine CCL2
Adiponectin

Keywords

  • Clinical science
  • Cytokines
  • Gastro-entero pancreatic factors
  • Human
  • Insulin sensitivity and resistance
  • Other hormones
  • Other islet cells/hormones
  • Weight regulation and obesity

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. / Swarbrick, M. M.; Stanhope, Kimber; Austrheim-Smith, I. T.; Van Loan, M. D.; Ali, Mohamed R; Wolfe, B. M.; Havel, Peter J.

In: Diabetologia, Vol. 51, No. 10, 10.2008, p. 1901-1911.

Research output: Contribution to journalArticle

Swarbrick, MM, Stanhope, K, Austrheim-Smith, IT, Van Loan, MD, Ali, MR, Wolfe, BM & Havel, PJ 2008, 'Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery', Diabetologia, vol. 51, no. 10, pp. 1901-1911. https://doi.org/10.1007/s00125-008-1118-5
Swarbrick, M. M. ; Stanhope, Kimber ; Austrheim-Smith, I. T. ; Van Loan, M. D. ; Ali, Mohamed R ; Wolfe, B. M. ; Havel, Peter J. / Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. In: Diabetologia. 2008 ; Vol. 51, No. 10. pp. 1901-1911.
@article{19c43ba4781549f48c078712a657dd67,
title = "Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery",
abstract = "Aims/hypothesis: Bariatric surgery is an effective treatment for severe obesity, as in addition to dramatic weight loss, co-morbidities such as type 2 diabetes are frequently resolved. Although altered gastrointestinal peptide hormone secretion and its relationship with post-surgical improvements in insulin sensitivity has been studied, much less is known about long-term changes in pancreatic and adipose tissue-derived hormones. Our objective was to conduct a comprehensive longitudinal investigation of the endocrine changes following Roux-en-Y gastric bypass surgery (RYGBP), focusing on pancreatic and adipocyte hormones and systemic markers of inflammation. Methods: Nineteen severely obese women (BMI 45.6±1.6 kg/m2) were studied prior to RYGBP, and at 1, 3, 6, and 12 months after RYGBP. Body composition was assessed before surgery and at 1 and 12 months. Results: Pre-surgical adiposity was correlated with circulating adipocyte hormones (leptin, visfatin) and inflammatory molecules (IL-6, high sensitivity C-reactive protein [hsCRP], monocyte chemoattractant protein-1). As expected, RYGBP reduced fat mass and fasting insulin and glucose concentrations. In addition, reductions of fasting pancreatic polypeptide (PP) and glucagon concentrations were observed at 1 and 3 months, respectively. In the 12 months following RYGBP, concentrations of most adipocyte hormones (leptin, acylation-stimulating hormone and visfatin, but not retinol-binding hormone-4) and inflammatory molecules (IL-6, hsCRP and soluble intracellular adhesion molecule-1) were significantly reduced. Reductions of insulin resistance (measured by homeostasis model assessment of insulin resistance) were independently associated with changes of glucagon, visfatin and PP. Pre-surgical HMW adiponectin concentrations independently predicted losses of body weight and fat mass. Conclusions/interpretation: These results suggest that pancreatic and adipocyte hormones may contribute to the long-term resolution of insulin resistance after RYGBP.",
keywords = "Clinical science, Cytokines, Gastro-entero pancreatic factors, Human, Insulin sensitivity and resistance, Other hormones, Other islet cells/hormones, Weight regulation and obesity",
author = "Swarbrick, {M. M.} and Kimber Stanhope and Austrheim-Smith, {I. T.} and {Van Loan}, {M. D.} and Ali, {Mohamed R} and Wolfe, {B. M.} and Havel, {Peter J}",
year = "2008",
month = "10",
doi = "10.1007/s00125-008-1118-5",
language = "English (US)",
volume = "51",
pages = "1901--1911",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery

AU - Swarbrick, M. M.

AU - Stanhope, Kimber

AU - Austrheim-Smith, I. T.

AU - Van Loan, M. D.

AU - Ali, Mohamed R

AU - Wolfe, B. M.

AU - Havel, Peter J

PY - 2008/10

Y1 - 2008/10

N2 - Aims/hypothesis: Bariatric surgery is an effective treatment for severe obesity, as in addition to dramatic weight loss, co-morbidities such as type 2 diabetes are frequently resolved. Although altered gastrointestinal peptide hormone secretion and its relationship with post-surgical improvements in insulin sensitivity has been studied, much less is known about long-term changes in pancreatic and adipose tissue-derived hormones. Our objective was to conduct a comprehensive longitudinal investigation of the endocrine changes following Roux-en-Y gastric bypass surgery (RYGBP), focusing on pancreatic and adipocyte hormones and systemic markers of inflammation. Methods: Nineteen severely obese women (BMI 45.6±1.6 kg/m2) were studied prior to RYGBP, and at 1, 3, 6, and 12 months after RYGBP. Body composition was assessed before surgery and at 1 and 12 months. Results: Pre-surgical adiposity was correlated with circulating adipocyte hormones (leptin, visfatin) and inflammatory molecules (IL-6, high sensitivity C-reactive protein [hsCRP], monocyte chemoattractant protein-1). As expected, RYGBP reduced fat mass and fasting insulin and glucose concentrations. In addition, reductions of fasting pancreatic polypeptide (PP) and glucagon concentrations were observed at 1 and 3 months, respectively. In the 12 months following RYGBP, concentrations of most adipocyte hormones (leptin, acylation-stimulating hormone and visfatin, but not retinol-binding hormone-4) and inflammatory molecules (IL-6, hsCRP and soluble intracellular adhesion molecule-1) were significantly reduced. Reductions of insulin resistance (measured by homeostasis model assessment of insulin resistance) were independently associated with changes of glucagon, visfatin and PP. Pre-surgical HMW adiponectin concentrations independently predicted losses of body weight and fat mass. Conclusions/interpretation: These results suggest that pancreatic and adipocyte hormones may contribute to the long-term resolution of insulin resistance after RYGBP.

AB - Aims/hypothesis: Bariatric surgery is an effective treatment for severe obesity, as in addition to dramatic weight loss, co-morbidities such as type 2 diabetes are frequently resolved. Although altered gastrointestinal peptide hormone secretion and its relationship with post-surgical improvements in insulin sensitivity has been studied, much less is known about long-term changes in pancreatic and adipose tissue-derived hormones. Our objective was to conduct a comprehensive longitudinal investigation of the endocrine changes following Roux-en-Y gastric bypass surgery (RYGBP), focusing on pancreatic and adipocyte hormones and systemic markers of inflammation. Methods: Nineteen severely obese women (BMI 45.6±1.6 kg/m2) were studied prior to RYGBP, and at 1, 3, 6, and 12 months after RYGBP. Body composition was assessed before surgery and at 1 and 12 months. Results: Pre-surgical adiposity was correlated with circulating adipocyte hormones (leptin, visfatin) and inflammatory molecules (IL-6, high sensitivity C-reactive protein [hsCRP], monocyte chemoattractant protein-1). As expected, RYGBP reduced fat mass and fasting insulin and glucose concentrations. In addition, reductions of fasting pancreatic polypeptide (PP) and glucagon concentrations were observed at 1 and 3 months, respectively. In the 12 months following RYGBP, concentrations of most adipocyte hormones (leptin, acylation-stimulating hormone and visfatin, but not retinol-binding hormone-4) and inflammatory molecules (IL-6, hsCRP and soluble intracellular adhesion molecule-1) were significantly reduced. Reductions of insulin resistance (measured by homeostasis model assessment of insulin resistance) were independently associated with changes of glucagon, visfatin and PP. Pre-surgical HMW adiponectin concentrations independently predicted losses of body weight and fat mass. Conclusions/interpretation: These results suggest that pancreatic and adipocyte hormones may contribute to the long-term resolution of insulin resistance after RYGBP.

KW - Clinical science

KW - Cytokines

KW - Gastro-entero pancreatic factors

KW - Human

KW - Insulin sensitivity and resistance

KW - Other hormones

KW - Other islet cells/hormones

KW - Weight regulation and obesity

UR - http://www.scopus.com/inward/record.url?scp=51249119175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51249119175&partnerID=8YFLogxK

U2 - 10.1007/s00125-008-1118-5

DO - 10.1007/s00125-008-1118-5

M3 - Article

C2 - 18704364

AN - SCOPUS:51249119175

VL - 51

SP - 1901

EP - 1911

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 10

ER -